The pet care landscape is shifting as biotechnology companies introduce increasingly sophisticated interventions aimed at extending animal lifespans and even preserving them after death. Pet owners seeking alternatives to traditional end-of-life decisions can now choose from pharmaceutical treatments, genetic duplication, and cryogenic storage—though experts question the wisdom of some approaches.
Longevity medications for aging pets
Loyal, a startup based in the United States, is currently developing three pharmaceutical compounds intended to extend canine lifespans. The company's lead candidate, LOY-002, functions as a daily oral medication for aging dogs and is undergoing clinical trials involving approximately 1,300 animals throughout the country.
During January, regulatory authorities in the US cleared Loyal's safety documentation for the drug—a procedural milestone that represents progress toward market authorization but does not constitute approval itself. The company has indicated its intention to seek conditional approval status by 2027.
Beyond Loyal's efforts, other organizations are investigating pharmaceutical solutions targeting age-related conditions in dogs, including weight management and joint deterioration. Separately, another firm is pursuing longevity therapeutics designed specifically for feline patients.
Genetic duplication at premium prices
The cloning process involves extracting genetic material from a living or deceased pet and transferring it into an unfertilized egg sourced from another member of the same species. Following this genetic transfer, a surrogate animal carries the resulting embryo to term.
Viagen Pets, headquartered in Texas, charges $50,000 to produce a cloned cat or dog, according to reporting by MIT Technology Review. While the resulting animal shares identical genetic material with the original, it does not replicate the personality or behavioral characteristics of the source animal.
Lori Kogan, a researcher at Colorado State University specializing in human-animal relationships, acknowledged that pet owners frequently experience grief that mainstream society fails to validate. Regarding cloning as a potential source of comfort, she posed the question: "who are we to judge?"
Cryogenic preservation and future revival
A small number of biotech firms have established services that preserve deceased pets through cryogenic freezing, operating under the premise that advancing scientific capabilities may eventually enable their resurrection. Alcor, an Arizona-based organization, maintains cryogenic storage for hundreds of animals and humans, and has recently added its first preserved pet sugar glider to its collection.
Scientific consensus holds that successful revival of cryopreserved organisms remains extraordinarily improbable. Jessica Hamzelou, writing for MIT Technology Review, expressed concern that both cloning and cryonics could convey misleading messages to young people regarding the permanence of death.
The biotechnology industry's focus on combating aging extends well beyond companion animals. Companies such as HexemBio are securing investment capital to develop rejuvenation treatments intended for human patients.
Source: The Next Web
